This meeting took place in 2017
Here are the related meetings in 2019:
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7)
Organizer(s) CheriƩ L. Butts, Amy S. Rosenberg, Amy D. Klion and Sachdev S. Sidhu
January 22—26, 2017
Snowbird Resort • Snowbird, Utah USA
Discounted Abstract Deadline: Sep 21, 2016
Abstract Deadline: Oct 20, 2016
Scholarship Deadline: Sep 21, 2016
Discounted Registration Deadline: Nov 21, 2016
Sponsored by Genmab A/S, ImmunoGen, Inc., Merck & Co., Inc., Mersana Therapeutics, Pfizer Inc. and Roche
Summary of Meeting:
The purpose of this meeting is to examine different approaches for treatment of cancer and other diseases (e.g., fibrosis, autoimmunity and inflammatory diseases). The program will provide insights from academic and industry scientists on innovative biologics technologies and treatment strategies for ameliorating disease in an effort to identify synergies and opportunities to cross-fertilize approaches. Furthermore, the meeting includes perspectives from the US Food & Drug Administration and how the outlined strategies will impact the drug review and approval process. The intention is to better inform meeting attendees of current/future strategies for treating disease and best practices for transforming concepts into approved drugs.
View Meeting Program
The purpose of this meeting is to examine different approaches for treatment of cancer and other diseases (e.g., fibrosis, autoimmunity and inflammatory diseases). The program will provide insights from academic and industry scientists on innovative biologics technologies and treatment strategies for ameliorating disease in an effort to identify synergies and opportunities to cross-fertilize approaches. Furthermore, the meeting includes perspectives from the US Food & Drug Administration and how the outlined strategies will impact the drug review and approval process. The intention is to better inform meeting attendees of current/future strategies for treating disease and best practices for transforming concepts into approved drugs.
View Meeting Program
Scholarships/Awards
National Institute of Allergy and Infectious Diseases (NIAID)/National Center for Advancing Translational Sciences (NCATS) Scholarship Recipients
Ken G. AnderssonRoyal Institute of Technology, Sweden
Kalie Mix
Massachusetts Institute of Technology, USA
Samuel Pollock
University of California, San Francisco, USA
Anna-Luisa Volk
Royal Institute of Technology, KTH, Sweden
Ellen Wagner
University of Texas at Austin, USA